SITE013-0196

SITE013 (USA) › SITE013-0196

SITE013-0196

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2026-04-29

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 133); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-21 (study day 111); relationship: not assessed

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 108); relationship: not assessed

mild assessed

Grade 2 Anaemia — outcome: UNKNOWN; onset 2022-12-12 (study day 40); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.